Market Overview

UPDATE: Oppenheimer Raises PT on Celldex Therapeutics on Key Clinical Milestones, Associated Trials Anticipated In 2H13

Related CLDX
Here's The Latest Biotech Breakout
This Biotech Stock Is Ready To Run

In a report published on Friday, Oppenheimer analyst Boris Peaker raised the price target on Celldex Therapeutics (NASDAQ: CLDX) from $14 to $16 and reiterated a rating of Outperform on the company.

In the report, Oppenheimer stated, "We believe that investors will be focused on the Rindo studies in brain cancer as well as initial data for CDX-1135 and CDX-1127. Additionally, we performed further due diligence on CDX-1135 and we are adding this compound to our valuation. This is the basis for our price target increase of $2/share (from $14 to $16)."

Celldex Therapeutics closed on Thursday at $14.29.

Latest Ratings for CLDX

DateFirmActionFromTo
Sep 2014Cowen & CompanyInitiates Coverage onOutperform
Jul 2013Guggenheim SecuritiesInitiates Coverage onBuy
Jun 2013OppenheimerMaintainsOutperform

View More Analyst Ratings for CLDX
View the Latest Analyst Ratings

Posted-In: Boris Peaker OppenheimerAnalyst Color Price Target Analyst Ratings

 

Related Articles (CLDX)

Around the Web, We're Loving...

Get Benzinga's Newsletters